A higher dose of the antibiotic rifampicin does not improve survival rates for patients with tuberculous meningitis. This severe form of tuberculosis causes inflammation of the brain membranes, and half of the patients die. These findings come from a large international study conducted by Radboud University Medical Center and its international partners. The research has now been published in the New England Journal of Medicine.
This article was originally published on MedicalXpress.com

